Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Domiphen→

Domiphen Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
13900-14-6
Molecular formula
C22H40NO+
Molecular weight
334.6 g/mol
Drug class
Quaternary ammonium antisepticcationic surfactant
Mechanism of action
Disrupts microbial cell membranes by interacting with membrane phospholipids and increasing permeability, causing leakage of intracellular contents.
Indications / reported uses
  • Local antiseptic use in selected oral, throat and topical preparations where domiphen bromide products are authorised; do not assign systemic antibacterial indications

Sources: NLM MeSH — Domiphen bromide · PubMed — Domiphen antiseptic · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Domiphen Environmental Risk Assessment (ERA) (the Domiphen ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.